| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.4 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.4 |